AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17403578 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injection of ET-1 (concentrations ranging from 10(‐10) to 10(‐6)M)
Number of subjects: 35
Study 17403578 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 35
Study 15384455 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpetration of domestic assault by a man
Number of subjects: 503
Study 15384455 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpetration of domestic assault by an African American perpetrator
Number of subjects: 503
Study 15384455 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who assault their husbands
Number of subjects: 503
Study 11295415 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (250mg bid)
Number of subjects: 40
Study 11295415 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (300mg bid)
Number of subjects: 40
Study 11295415 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 40
Study 11295415 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 40
Study 11295415 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and Ofloxacin
Number of subjects: 40
Study 10205329 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed guar gum (BENEFIBER)
Number of subjects: 10
Study 10205329 — intervention group
Group type: COMPARATOR
Intervention: Liquid formula diet without fibre
Number of subjects: 10
Study 7960618 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol (0.5 mmol/kg)
Number of subjects: 91
Study 7960618 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol (0.04, 0.1, 0.4 mmol/kg)
Number of subjects: 91
Study 7960618 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol (various doses)
Number of subjects: 91
Study 3302916 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate penicillin treatment
Number of subjects: 142
Study 3302916 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (48 to 56 hours)
Number of subjects: 142
Study 3302916 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (aspirin or acetaminophen)
Number of subjects: 142
Study 31512155 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone and text message support in addition to standard OMS care
Number of subjects: 61
Study 31512155 — intervention group
Group type: COMPARATOR
Intervention: Standard OMS care alone
Number of subjects: 61
Study 29407564 — intervention group
Group type: EXPERIMENTAL
Intervention: Response Inhibition Training (RIT)
Number of subjects: 22
Study 29407564 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted Control (WLT)
Number of subjects: 22
Study 27373755 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified peanut butter paste
Number of subjects: 968
Study 27373755 — intervention group
Group type: EXPERIMENTAL
Intervention: Food purchasing at school
Number of subjects: 968
Study 27373755 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of fish
Number of subjects: 968
Study 24022677 — intervention group
Group type: EXPERIMENTAL
Intervention: Yearly Family Check-Ups (FCUs)
Number of subjects: 731
Study 24022677 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 731
Study 22042749 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg per day
Number of subjects: 50
Study 22042749 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray 400 µg twice daily
Number of subjects: 50
Study 22042749 — intervention group
Group type: COMPARATOR
Intervention: Eosinophils in peripheral blood
Number of subjects: 50
Study 20705534 — intervention group
Group type: EXPERIMENTAL
Intervention: MK‐8141 250 mg
Number of subjects: 195
Study 20705534 — intervention group
Group type: EXPERIMENTAL
Intervention: MK‐8141 500 mg
Number of subjects: 195
Study 20705534 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg
Number of subjects: 195
Study 20705534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 17569711 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.60 mg/kg of body weight
Number of subjects: 122
Study 17569711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 15730599 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline plus placebo (group 1)
Number of subjects: 40
Study 15730599 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline plus placebo (group 2)
Number of subjects: 40
Study 15730599 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline and terbutaline together (group 3)
Number of subjects: 40
Study 11899738 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10567626 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (100 mg)
Number of subjects: 16
Study 8918323 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU/kg once-daily dalteparin (group 1)
Number of subjects: 140
Study 8918323 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU/kg twice-daily dalteparin (group 2)
Number of subjects: 140
Study 8918323 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 140
Study 1717341 — intervention group
Group type: COMPARATOR
Intervention: Nd:YAG laser recanalization alone (N = 20)
Number of subjects: 39
Study 1717341 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser recanalization and subsequent endoluminal afterloading irradiation with iridium-192 at a dose of 3 x 7 Gy (6 x 7 Gy)
Number of subjects: 39
Study 6749604 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (30 g)
Number of subjects: 7
Study 6749604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 6749604 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (30 g) for longer periods (5 to 22 weeks)
Number of subjects: 7
Study 6749604 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids
Number of subjects: 7
Study 31377925 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized virtual reading center interpretation
Number of subjects: 1902
Study 31377925 — intervention group
Group type: COMPARATOR
Intervention: Pre-centralization interpretation by ophthalmologists
Number of subjects: 1902
Study 31377925 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-centralization interpretation by optometrists
Number of subjects: 1902
Study 30352291 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention including an in-person educational session, an informative leaflet, and two phone-based sessions at 1 and 6 months.
Number of subjects: 0
Study 30352291 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 0
Study 30352291 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention.
Number of subjects: 0
Study 27612281 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide-SC
Number of subjects: 0
Study 26257021 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose (40 μg) recombinant hepatitis B vaccine at weeks 0, 4, and 24
Number of subjects: 178
Study 26257021 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose (20 μg) recombinant hepatitis B vaccine at weeks 0, 4, and 24
Number of subjects: 178
Study 26257021 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose (40 μg) group
Number of subjects: 178
Study 26257021 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose (20 μg) group
Number of subjects: 178
Study 24979519 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine A (CsA) 0.05% eyedrops
Number of subjects: 62
Study 24979519 — intervention group
Group type: COMPARATOR
Intervention: Placebo (artificial tears)
Number of subjects: 62
Study 22435114 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioral therapy (CBT) for 12 weeks
Number of subjects: 50
Study 22435114 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 50
Study 19397693 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin/fenofibrate (80/200 mg)
Number of subjects: 75
Study 19397693 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin/ezetimibe (20/10 mg)
Number of subjects: 75
Study 17321817 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorized scooter for 3 months
Number of subjects: 22
Study 17321817 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 22
Study 17321817 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorized scooter usage
Number of subjects: 22
Study 17321817 — intervention group
Group type: EXPERIMENTAL
Intervention: Accidents while using the scooter
Number of subjects: 22
Study 17321817 — intervention group
Group type: EXPERIMENTAL
Intervention: Scooter usage in diverse locations
Number of subjects: 22
Study 15114043 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional acupuncture (TCM group, n = 27)
Number of subjects: 51
Study 15114043 — intervention group
Group type: COMPARATOR
Intervention: Control treatment at non-acupuncture points (control group, n = 24)
Number of subjects: 51
Study 15114043 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional acupuncture (TCM group)
Number of subjects: 51
Study 10831139 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological attachment measure (compulsive care-seeking, angry withdrawal, compulsive self-reliance)
Number of subjects: 209
Study 10831139 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment pathology and insecure attachment style
Number of subjects: 209
Study 9113548 — intervention group
Group type: EXPERIMENTAL
Intervention: Midvastus muscle-splitting approach
Number of subjects: 118
Study 9113548 — intervention group
Group type: COMPARATOR
Intervention: Medial parapatellar approach
Number of subjects: 118
Study 7508973 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HCV positive patients
Number of subjects: 150
Study 7508973 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg positive patients
Number of subjects: 150
Study 7508973 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg carriers
Number of subjects: 150
Study 7508973 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg alone
Number of subjects: 150
Study 7508973 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HCV alone
Number of subjects: 150
Study 7508973 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HBsAg and anti-HCV positive
Number of subjects: 150
Study 7508973 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-attributable risk for anti-HCV alone
Number of subjects: 150
Study 7508973 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-attributable risk for HBsAg alone
Number of subjects: 150
Study 7508973 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-attributable risk for both anti-HCV and HBsAg
Number of subjects: 150
Study 2993687 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (5 g)
Number of subjects: 20
Study 2993687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2451578 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml dextran 70 in saline solution
Number of subjects: 10
Study 2451578 — intervention group
Group type: COMPARATOR
Intervention: 10 ml saline solution (control)
Number of subjects: 10
Study 30181338 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin (10 IU in 1 mL given slowly over one minute)
Number of subjects: 1075
Study 30181338 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular oxytocin (10 IU in 1 mL)
Number of subjects: 1075
Study 28898104 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided barbotage combined with a subacromial corticosteroid injection (SAIC)
Number of subjects: 48
Study 28898104 — intervention group
Group type: COMPARATOR
Intervention: Isolated ultrasound-guided SAIC
Number of subjects: 48
Study 28898104 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 26399868 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfeeding (+50% of energy needs for 1 week)
Number of subjects: 32
Study 26399868 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR, -50% of energy needs for 3 weeks)
Number of subjects: 32
Study 26399868 — intervention group
Group type: EXPERIMENTAL
Intervention: Refeeding (+50% of energy needs for 2 weeks)
Number of subjects: 32
Study 24617124 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (35-40 min/day, 5 days a week for 18 months)
Number of subjects: 258
Study 24617124 — intervention group
Group type: COMPARATOR
Intervention: Non-yoga group (control)
Number of subjects: 258
Study 21428979 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol cream applied twice daily for 7 days before photoprovocation testing
Number of subjects: 13
Study 21428979 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied twice daily for 7 days before photoprovocation testing
Number of subjects: 13
Study 19278080 — intervention group
Group type: EXPERIMENTAL
Intervention: Baking soda dentifrice
Number of subjects: 207
Study 19278080 — intervention group
Group type: EXPERIMENTAL
Intervention: Baking soda dentifrice (single brushing)
Number of subjects: 207
Study 19278080 — intervention group
Group type: COMPARATOR
Intervention: Triclosan dentifrice
Number of subjects: 207
Study 19278080 — intervention group
Group type: COMPARATOR
Intervention: Triclosan dentifrice (single brushing)
Number of subjects: 207
Study 17136289 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment with proton pump inhibitors for GERD symptoms and esophageal injury.
Number of subjects: 0
Study 17136289 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment for GERD when esophageal symptoms are absent.
Number of subjects: 0
Study 17136289 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of pharmacological treatment for GERD.
Number of subjects: 0
Study 12920409 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid initial dose escalation (RIDE) of up to 40 mg of oral olanzapine on days 1 and 2, up to 30 mg on days 3 and 4, and 5 to 20 mg thereafter
Number of subjects: 148
Study 12920409 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical practice (UCP) with 10 mg/d olanzapine plus up to 4 mg lorazepam on days 1 and 2, up to 2 mg on days 3 and 4, and olanzapine 5 to 20 mg/d thereafter
Number of subjects: 148
Study 10870534 — intervention group
Group type: EXPERIMENTAL
Intervention: Management guided by a clinical pathway (55 patients)
Number of subjects: 111
Study 10870534 — intervention group
Group type: COMPARATOR
Intervention: Established standard of care (control group, 56 patients)
Number of subjects: 111
Study 9292632 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.75 mg) administered on days 2 and 11
Number of subjects: 7
Study 9292632 — intervention group
Group type: COMPARATOR
Intervention: No capsule administered on days 1 and 9
Number of subjects: 7
Study 9292632 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered on days 3 and 10
Number of subjects: 7
Study 8385974 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01 mg kg‐1 intravenously (i.v.)
Number of subjects: 21
Study 8385974 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg kg‐1 intravenously (i.v.)
Number of subjects: 21
Study 8385974 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg kg‐1 orally (p.o.)
Number of subjects: 21
Study 8385974 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg kg‐1 intravenously (i.v.)
Number of subjects: 21
Study 8385974 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg kg‐1 intravenously (i.v.)
Number of subjects: 21
Study 8385974 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg kg‐1 orally (p.o.)
Number of subjects: 21
Study 8385974 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg kg‐1 orally (p.o.) and 0.3 mg kg‐1 orally (p.o.)
Number of subjects: 21
Study 8385974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dosing
Number of subjects: 21
Study 8385974 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 21
Study 3519094 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release formulation of ketoprofen
Number of subjects: 8
Study 3519094 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard formulation of ketoprofen
Number of subjects: 8
Study 30635020 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg orally three times a day
Number of subjects: 360
Study 29554173 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal 10-μg estradiol tablet (daily for 2 weeks, then twice weekly) plus placebo gel (3 times a week)
Number of subjects: 302
Study 29554173 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal moisturizer
Number of subjects: 302
Study 29554173 — intervention group
Group type: COMPARATOR
Intervention: Dual placebo (placebo tablet plus vaginal gel)
Number of subjects: 302
Study 29554173 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal 10-μg estradiol tablet
Number of subjects: 302
Study 27189156 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-tip cryoballoon (ST CB)
Number of subjects: 64
Study 27189156 — intervention group
Group type: COMPARATOR
Intervention: Advance cryoballoon (ADV CB)
Number of subjects: 64
Study 25605283 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine (Cfz) therapy group (n = 53)
Number of subjects: 105
Study 25605283 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 52)
Number of subjects: 105
Study 23046862 — intervention group
Group type: EXPERIMENTAL
Intervention: Phaseolus vulgaris extract (PVE) 100 mg
Number of subjects: 12
Study 23046862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21964222 — intervention group
Group type: EXPERIMENTAL
Intervention: PLISSIT model sexual program
Number of subjects: 61
Study 21964222 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 22073466 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction osteogenesis (DO)
Number of subjects: 0
Study 22073466 — intervention group
Group type: COMPARATOR
Intervention: Conventional osteotomies (CO)
Number of subjects: 0
Study 16983393 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg daily for 2 years)
Number of subjects: 161
Study 12826249 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent paclitaxel with external beam radiotherapy
Number of subjects: 0
Study 12826249 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent paclitaxel and gemcitabine with RT followed by R115777
Number of subjects: 0
Study 12826249 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative chemoirradiation (5‐fluorouracil before, after, and during RT)
Number of subjects: 0
Study 12826249 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine given concurrently with RT
Number of subjects: 0
Study 11232071 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on audit and feedback with opportunity for reflection on practice
Number of subjects: 46
Study 11232071 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 46
Study 9355184 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon green laser treatment applied directly to the soft drusen in the temporal macula (Group 1)
Number of subjects: 46
Study 9355184 — intervention group
Group type: COMPARATOR
Intervention: Control (fellow eye in Group 1)
Number of subjects: 46
Study 9355184 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon green laser treatment applied directly to the soft drusen in the temporal macula (Group 2)
Number of subjects: 46
Study 8471778 — intervention group
Group type: EXPERIMENTAL
Intervention: FTBI/VP‐16
Number of subjects: 122
Study 8471778 — intervention group
Group type: COMPARATOR
Intervention: BU/CY
Number of subjects: 122
Study 8471778 — intervention group
Group type: EXPERIMENTAL
Intervention: CSA/PSE
Number of subjects: 122
Study 3016111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal recombinant interferon (rIFN; 2 X 10(6) IU/day)
Number of subjects: 55
Study 3016111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 30129268 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-tufted toothbrush and conventional toothbrush combination (Group 3)
Number of subjects: 20
Study 30129268 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-tufted toothbrush (Group 2)
Number of subjects: 20
Study 30129268 — intervention group
Group type: COMPARATOR
Intervention: Conventional toothbrush (Group 1)
Number of subjects: 20
Study 28028253 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy regimen of S‐1 combined with weekly intravenous and IP paclitaxel (PTX) administration, with a recommended dose of IP PTX being 20 mg/m2.
Number of subjects: 0
Study 28028253 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy regimen of S‐1 combined with weekly intravenous and IP paclitaxel (PTX) administration for P1 gastric cancer.
Number of subjects: 0
Study 28028253 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal chemotherapy (IP chemotherapy)
Number of subjects: 0
Study 28028253 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal administration of docetaxel
Number of subjects: 0
Study 26061040 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring for HIV-1 prevention
Number of subjects: 2629
Study 26061040 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 2629
Study 23929781 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia (defined as baseline Hb <13 g/dL in men and <12 g/dL in women)
Number of subjects: 2331
Study 23929781 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 2331
Study 20575281 — intervention group
Group type: COMPARATOR
Intervention: Trapezoid compression plate
Number of subjects: 57
Study 20575281 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic plate
Number of subjects: 57
Study 18087204 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance antidepressant (AD) medication
Number of subjects: 172
Study 18087204 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent use of antidepressants
Number of subjects: 172